Table 2.

Summary of efficacy outcomes

Variables	RT + PD1, N = 37 (%)	TACE + Sorafenib, N = 41(%)	P value
According to RECIST 1.1
Confirmed objective response	20 (54.05%)	5(12.20%)	< 0.001
Time to response, months, (IQR)	1.80(1.57–2.00)	2.87(1.407–6.86)	0.467
Disease control	26(70.27%)	19(46.34%)	0.041
Best overall response
CR	0(0)	0(0)	1.000
PR	20 (54.05%)	5(12.20%)	< 0.001
SD	6(16.22%)	14(34.15%)	0.118
PD	11(29.73%)	22(53.66%)	0.041
Progression-free survival, months, median, (95% CI)	5.86(3.19–8.53)	3.70(2.60–4.80)	0.017
According to mRECIST
Confirmed objective response	21(56.76%)	13(31.71%)	0.039
Time to response, months, (IQR)	1.85(1.60–2.98)	1.47(0.80–2.60)	0.061
Disease control	26(70.27%)	19(46.34%)	0.041
Best overall response
CR	1(2.70%)	1(2.44%)	1.000
PR	20 (54.05%)	12(29.27%)	0.038
SD	5(13.51%)	6(14.63%)	0.774
PD	11(29.73%)	22(53.66%)	0.041
Progression-free survival, months, median, (95% CI)	5.86(3.19–8.53)	3.70(2.60–4.80)	0.019
Overall survival
3-month, %	97.30%	92.30%	< 0.001
6-month, %	91.90%	68.60%	< 0.001
9-month, %	75.50%	60.60%	< 0.001
12-month, %	52.20%	47.5%	0.061
Overall survival, months, median, (95% CI)	17.40 (8.69–26.11)	11.90 (6.35–17.45)	0.146

Data are N (%; 95% CI), unless indicated

RT Radiotherapy; PD1 The monoclonal antibody against programmed cell death 1; TACE Transcatheter arterial chemoembolization; RECIST 1.1 Response Evaluation Criteria in Solid Tumors 1.1; mRECIST Modified Response Evaluation Criteria in Solid Tumors; CR Complete response; PR Partial response; SD Stable disease; PD Progressive disease